NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-AT-24-048 from the NIH Guide for Grants and Contracts
Notice NOT-GM-24-038 from the NIH Guide for Grants and Contracts
Notice NOT-GM-24-035 from the NIH Guide for Grants and Contracts
Notice NOT-DE-25-031 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AI-24-029 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support basic and applied research to define the mechanisms for establishing, developing and maintaining immunity to HIV in early life (from birth to less than 12 years of age), including the impact of prophylactic vaccination and broadly neutralizing HIV antibodies (bNAbs) to protect against acquisition of HIV infection.
Notice NOT-CA-24-061 from the NIH Guide for Grants and Contracts
Notice NOT-CA-24-062 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-MD-24-009 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to support research that includes education, outreach, and clinical access to improve the screening, diagnosis, and treatment of cancers among American Indians and Alaska Natives, particularly those living in rural communities.
Funding Opportunity PAR-24-239 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support highly innovative mechanistic research to accelerate precision probiotic interventions. Specifically, this NOFO solicits R33 applications that will characterize person-specific features affecting probiotic responses to identify subgroups of probiotic responders and to enhance probiotic clinical outcomes. The ultimate goal of this NOFO is to identify, understand, and develop strategies to address barriers in precision probiotic therapies to account for the heterogenicity in humans that causes inconsistent probiotic responses. This NOFO will support studies to assess the ability of the unique patterns of host biology (e.g., native microbiome, immune system, gender, diet, age, genetic background, lifestyle, and health history) that are correlated with probiotic usage to detect the improvement of probiotic responsiveness. Well-suited applications must offer rigorously designed mechanistic studies using relevant/innovative animal models or in human subjects. This NOFO is intended to support projects where potential host biological patterns that are correlated with probiotic usage have been identified, as demonstrated with supportive preliminary data, but require further mechanistic studies to test for their causality or predictability. Applicants pursuing early-stage research to identify host biological patterns that may affect probiotic health outcomes should consider the companion (R61/R33) NOFO PAR-AT-24-XXX (TEMP-25412).
Funding Opportunity PAR-24-238 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support highly innovative mechanistic research to accelerate precision probiotic interventions using a milestone-driven, biphasic award mechanism, R61/R33 Phased Innovation Award. Specifically, this NOFO solicits applications that will characterize person-specific features affecting probiotic responses to identify subgroups of probiotic responders and to enhance probiotic clinical outcomes. The ultimate goal of this NOFO is to identify, understand, and develop strategies to address barriers in precision probiotic therapies to account for the heterogenicity in humans that causes inconsistent probiotic responses. The first phase, funded by the R61, will providing for up to 2 years to identify unique host biological patterns (e.g., native microbiome, immune system, gender, diet, age, genetic background, lifestyle, and health history) that are correlated with heterogeneity of probiotic clinical effects using observational or secondary data analysis studies. The second phase, funded under the R33, will support studies to assess the ability of the unique patterns determined in the R61 phase to detect the improvement of probiotic responsiveness in rigorously designed mechanistic studies in relevant animal models or in human subjects. The combined R61/R33 should not exceed 5 years. Transition from the R61 to the R33 phase of the award will be administratively reviewed and will be determined based on successful completion of Transition Milestones that need to be clearly specified in the R61 phase application. Support for a single phased award that does not need the R61 Exploratory phase is available in the companion (R33) NOFO, PAR-AT-24-XXX (TEMP-25413).
Notice NOT-AG-24-025 from the NIH Guide for Grants and Contracts
Notice NOT-DC-24-034 from the NIH Guide for Grants and Contracts
Notice NOT-OD-24-145 from the NIH Guide for Grants and Contracts
Notice NOT-CA-24-068 from the NIH Guide for Grants and Contracts
Notice NOT-DE-25-029 from the NIH Guide for Grants and Contracts
Notice NOT-PM-24-004 from the NIH Guide for Grants and Contracts
Notice NOT-OD-24-132 from the NIH Guide for Grants and Contracts
Notice NOT-EY-24-012 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-MH-25-180 from the NIH Guide for Grants and Contracts. The goals of this initiative are to examine mechanisms of reciprocal interactions between HIV-associated neuroinflammation and CNS persistence in the setting of excellent virologic control using novel CNS cell systems, organoid models and single cell technologies
Funding Opportunity RFA-MH-25-181 from the NIH Guide for Grants and Contracts. The goals of this initiative are to examine mechanisms of reciprocal interactions between HIV-associated neuroinflammation and CNS persistence in the setting of excellent virologic control using novel CNS cell systems, organoid models and single cell technologies